Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Food Industry News Our Home expands snack portfolio with acquisition of Sonoma Creamery Our Home, a leading family of brands known for providing wholesome snacks across the U.S., has announced the… byPallavi MadhirajuMay 3, 2024